Drug intelligence / Profile preview

AVCN467504

Development stage: Unknown
Lead developer: Avicanna
Modality: Small Molecules
Administration: Topical

Overview

AVCN467504 is a topical cannabinoid-based pharmaceutical candidate developed by Avicanna for the treatment of local inflammatory pain. The asset utilizes a proprietary topical delivery system to deliver cannabinoids locally to affected tissues, aiming to reduce inflammation and provide analgesic effects without significant systemic exposure. As of 2024, the program is listed in Avicanna's pharmaceutical pipeline as being in the Phase 2/3 stage of development, following the collection of real-world evidence (RWE).

Beyond the preview

Go deeper on AVCN467504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVCN467504.

Explore the full profile